Purpose: Triple negative breast cancer (TNBC) is the most lethal and 31 aggressive subtype of breast cancer. AMP-activated protein kinase (AMPK) is a major 32 energy regulator that suppresses tumor growth, and 1-(3-chloro-4-33 ((trifluoromethyl)thio)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea (FND-4b) is a novel 34 AMPK activator that inhibits growth and induces apoptosis in colon cancer. The purpose 35 of this project was to test the effects of FND-4b on AMPK activation, proliferation, and 36 apoptosis in breast cancer with a particular emphasis on TNBC. 37 Materials and methods: (i) Estrogen-receptor positive breast cancer (ER+BC; 38 MCF-7, and T-47D), TNBC (MDA-MB-231 and HCC-1806), and breast cancer stem cells 39 were treated with FND-4b for 24h. Immunoblot analysis assessed AMPK, acetyl-CoA 40 carboxylase (ACC), ribosomal protein S6, cyclin D1, and cleaved PARP. (ii) 41 Sulforhodamine B growth assays were performed after treating ER+BC and TNBC cells 42 with FND-4b for 72h. Proliferation was also assessed by counting cells after 72h of FND-43 4b treatment. (iii) Cell death ELISA assays were performed after treating ER+BC and 44 TNBC cells with FND-4b for 72h. 45 Results: (i) FND-4b increased AMPK activation with concomitant decreases in 46 ACC activity, phosphorylated S6, and cyclin D1 in all subtypes. (ii) FND-4b decreased 47 proliferation in all cells, while dose-dependent growth decreases were found in ER+BC 48 and TNBC. (iii) Increases in apoptosis were observed in ER+BC and the MDA-MB-231 49 cell line with FND-4b treatment. 50 Conclusions: Our findings indicate that FND-4b decreases proliferation for a 51 variety of breast cancers by activating AMPK and has notable effects on TNBC. The 52 growth reductions were mediated through decreases in fatty acid synthesis (ACC), 53 mTOR signaling (S6), and cell cycle flux (cyclin D1). ER+BC cells were more susceptible 54 to FND-4b-induced apoptosis, but MDA-MB-231 cells still underwent apoptosis with 55 higher dose treatment. Further development of FND compounds could result in a novel 56 therapeutic for TNBC. 57 almost 41,000 deaths [1]. Up to 30% of patients develop metastases, and 90% of deaths 62 result from metastases to the lung, brain, or bone [2]. Breast cancer is a heterogeneous 63 disease separable into three main types: estrogen-receptor positive breast cancer 64 (ER+BC), HER2-amplified breast cancer, and triple negative breast cancer (TNBC). 65 of anabolic and oncogenic pathways, (2) attenuated mTOR signaling, (3) decreased cell 87 proliferation, and (4) apoptosis [17-26]. Well-known AMPK activators, such as 5-88 aminoimidazole-4-carboxamide ribonucleotide (AICAR) and 2-deoxyglucose (2-DG), 89
Introduction

58
Breast cancer is the most common cancer in women and the main cause of 59 cancer-related death among women worldwide. In 2018 alone, there will be more than 60 266,000 newly diagnosed cases of breast cancer in women in the United States and 61 aggressive of the three types [3, 4] . 67
The principal characteristics of TNBC include: (1) reduced expression of the 68 estrogen and progesterone receptors and (2) no overexpression of HER2. TNBC affects 69 a younger patient population than the population afflicted with other types of breast 70 cancer and leads to an increased risk of recurrence and metastases [3] . Not surprisingly, 71 patients with recurrent TNBC have a worse prognosis than that for patients with 72 recurrent forms of other breast cancers [3] . In addition, patients with TNBC have limited 73 therapeutic options because their tumors lack the traditional steroid hormone receptors 74 and HER2 amplification. Instead, patients usually receive a drug cocktail that includes an 75 anthracycline antineoplastic agent, a DNA alkylating agent, and a taxane [3] . These 76 chemotherapeutic agents are toxic to normal and cancer cells alike and result in serious 77 side-effects that are difficult for patients to tolerate. Recent efforts have focused on 78 developing therapies that specifically target cancer cells without affecting normal cells. 79
Because oncogenic transformation requires major metabolic reprogramming to produce 80 energy, redox cofactors, and molecules involved in DNA modification, new agents that 81 target the increased metabolism within cancer tissue more than the metabolism in 82 normal tissue are attractive therapeutic options [2] . 83 AMP-activated protein kinase (AMPK) is a cellular energy sensor that has 84 important implications in cancer progression [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . When activated by ATP depletion, 85 the phosphorylated form of AMPK causes the following changes in TNBC: (1) inhibition 86 Sulforhodamine B (SRB) Cytotoxicity Assay was from G-Biosciences (St. Louis, MO). 116
The Cell Death Detection ELISA PLUS assay was from Cell culture 118 MCF-7, T-47D, MDA-MB-231, HCC-1143, and HCC-1806 cells were purchased 119 from ATCC, while breast cancer stem cells were purchased from Celprogen. MCF-7 120 cells were maintained in EMEM containing 10% FBS, 1% P/S, 0.01 mg/mL insulin, 1x 121 non-essential amino acids, and 1 mM sodium pyruvate. T-47D cells were maintained in 122 RPMI containing 10% FBS, 1% P/S, and 0.2 Units/mL insulin. MDA-MB-231, HCC-1143, 123 and HCC-1806 cells were maintained in RPMI with 10% FBS and 1% P/S. Breast cancer 124 stem cells were maintained in breast cancer stem cell medium supplemented with 10% 125 FBS and 1% P/S. All cells were grown in an incubator at 37°C and 5% CO2. For cell 126 treatments, 7x10 5 MCF-7 and T-47D cells or 8x10 5 MDA-MB-231, HCC-1806, and 127 breast cancer stem cells were seeded in 6-well plates and incubated overnight. The 128 medium was removed on the following day, and cells were treated with fresh medium 129 that contained different concentrations of FND-4b (0, 1, 2.5, 5, 10, and 20 µM) for 24 h 130 before lysis. 131 6 saline with 0.1% tween-20 (TBST) for 5 min and again for 10 min. The membranes were 141 subsequently incubated with the appropriate secondary antibody for 30 min at room 142 temperature. The membranes were then washed with TBST for 15 min and again for 20 143 min. Proteins were visualized with Amersham ECL (GE Healthcare) or Immobilon 144 (Millipore). Membranes were stripped and reprobed as necessary. 145
Cell counting assay 146 Cells (1x10 5 ) were seeded in 6-well plates and incubated overnight. The medium 147 was removed on the following day, and cells were grown in fresh medium that contained 148 0 or 5 µM FND-4b for 72 h. Cells were then washed with PBS, trypsinized, and counted 149 with a Beckman-Coulter cell counter. 150 SRB growth assay 151 Cells (5x10 3 in 100 µL) were seeded in 96-well plates and incubated overnight. 152
On the following day, fresh media was prepared to contain twice the desired 153 concentrations of 5, 10, 20, and 40 µM) . Then 100 µL of the new media 154 solutions were added to the wells without removing the old media; this yielded 200 µL 155 per well and halved the FND-4b concentrations. Cells were grown in the media with 156 different final concentrations of FND-4b (0, 2.5, 5, 10, and 20 µM) for 72 h before the 157 proteins were fixed at 4°C for 1 h. The wells were washed 3 times with water and then 158 dried for 30 min. The SRB dye solution (0.4%) was added to the wells and incubated for 159 30 min. The excess dye was washed off with 1% acetic acid, and the wells were allowed 160 to air dry. The dye was solubilized with a 10 mM Tris solution, and the absorbance was 161 measured at 565 nm or-if the readings were outside of the instrument's linear range-162 at 490 nm. 163 Cells (5x10 3 in 100 µL) were seeded in 96-well plates and incubated overnight. 165
On the following day, fresh media was prepared to contain twice the desired 166 concentrations of 5, 10, and 20 µM) . Then 100 µL of the new media 167 solutions were added to the wells without removing the old media; this yielded 200 µL 168 per well and halved the FND-4b concentrations. Cells were cultured in the media with 169 different final concentrations of FND-4b (0, 2.5, 5, and 10 µM) for 72 h. Cells were then 170 centrifuged at 200 x g for 10 min and lysed for 30 min with shaking. The lysates were 171 centrifuged at 200 x g for 10 min, and 20 µL of supernatant was transferred to 172 streptavidin-coated wells. Then 80 µL of the immunoreagent (anti-histone biotin and anti-173 DNA peroxidase) was added to the streptavidin-coated wells. The plates were shaken 174 for 2 h at room temperature before the wells were rinsed three times with incubation 175 buffer. Color change was initiated by adding the substrate ABTS to the wells, and the 176 plates were shaken until the color change was sufficient for photometric analysis. After 177 adding the ABTS Stop Solution, absorbance was measured at 405 nm. 178
Statistical analysis 179
Comparisons of SRB growth and ELISA assays across non-treated and different 180 dose groups of FND-4b were performed using analysis of variance (ANOVA) with test for 181 linear trend across dose levels. Pairwise comparisons of each FND-4b dose level versus 182 non-treated group were performed within the ANOVA model with Holm's p-value 183 adjustment for multiple testing. Comparisons of cell counting assays between control 184 and FND-4b-treated groups were performed using two-sample t-tests with homogeneity 185 of variance assessed for the use of the t-test for two group comparisons. Analyses were 186 performed on data normalized with the non-treated group for the SRB growth and cell 187 counting assays and on the raw data for the ELISA assays. In all experiments, p-values 188 less than 0.05 were considered significant. 189 Prior work has suggested that TNBC cell lines and tissues have higher levels of 193 phosphorylated and total forms of AMPKα than non-TNBC cells and tissues [29] . 194
Results
190
Analysis of pAMPKα expression in breast cancer
Consequently, we compared levels of pAMPKα and total AMPKα in TNBC and ER+BC 195 cells using western blotting. We found no difference in levels of phosphorylated or total 196
AMPKα between two ER+BC cell lines (MCF-7 and T-47D) and three TNBC cell lines 197 (MDA-MB-231, HCC-1143, and HCC-1806) (Fig 1) . AMPKα has been implicated as a tumor suppressor in breast cancer [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . 236
Since FND-4b activated AMPKα, we measured its effects on the growth of breast cancer 237 cells. Cell counting assays showed that treatment at 5 µM FND-4b for 72 h resulted in 238 significant growth inhibition of MCF-7, T-47D, MDA-MB-231, HCC-1806, and breast 239 cancer stem cells (Fig 3A) . Similar decreases occurred in all breast cancer subtypes 240 with 5 µM treatment. In addition, SRB growth assays indicated that treatment at various 241 FND-4b concentrations (2.5, 5, 10, and 20 µM) for 72 h yielded significant dose-242 dependent decreases in proliferation of MCF-7, T-47D, MDA-MB-231, and HCC-1806 243 cells (Fig 3B) . ER+BC cells were more sensitive than TNBC cells to FND-4b at 2.5 µM, 244 but the reductions were similar at higher concentrations. Similar growth inhibition at the 5 245 µM dosage between ER+BC and TNBC is consistent with the results from the cell 246 counting assays. Taken together, these results illustrate that activation of AMPKα with 247 FND-4b resulted in dose-dependent decreases in growth in ER+BC and TNBC. 248 
FND-4b increased apoptosis in ER+BC and TNBC
258
While FND-4b's major effect is on cell growth, its treatment also increased 259 apoptosis in colon cancer [27] . Therefore, we investigated apoptosis induction in breast 260 cancer cells. As previously mentioned, treatment with FND-4b resulted in increased 261 levels of cleaved PARP, a marker of apoptosis, in MDA-MB-231, HCC-1806, and MCF-7 262 cells (see Fig 2) . We also measured apoptosis with ELISA cell death assays that are 263 more sensitive than western blotting assays. Significant increases in apoptosis were 264 found in MCF-7 and T-47D cells-with MCF-7 cells being more sensitive (Fig 4A-B) . 265
Apoptosis was significantly increased in MDA-MB-231 cells with treatment at 10 µM 266 FND-4b, but apoptosis in HCC-1806 cells was not increased (Fig 4C-D) . 
Discussion
275
The connection between AMPK activation and the inhibition of cancer cell growth 276 prompted our interest in targeting AMPK and its downstream signaling pathways. AMPK 277 activators such as AICAR and 2-DG have limited utility for patient care due to their high 278 dose requirements [12] . We focused on novel small-molecule agents that activated 279 AMPK at low concentrations and that stood a greater chance than these well-known 280 AMPK activators of progressing toward the clinic. In this project, we examined the 281 effects of the AMPK activator FND-4b to determine its effects on ER+BC, TNBC, and 282 breast cancer stem cells. FND-4b previously suppressed the growth of colorectal cancer 283 cells and stem cells through activation of AMPK in the low micromolar range without 284 affecting signaling through the Akt or ERK pathways [27, 28] . We found that treatment 285 with FND-4b resulted in dose-dependent increases in AMPK activation in both breast 286 cancer subtypes and in the stem cells. 287
Other investigators have also focused on discovering novel AMPK activators or 288 repurposing current drugs that activate AMPK for breast cancer therapy. OSU-53 and 289 RL-71 activated AMPK and exerted anti-tumor effects in TNBC at low micromolar doses 290 [17, 19] . In addition, demethoxycurcumin (20 µM) resulted in AMPK activation and large 291 decreases in TNBC and ER+BC cell proliferation [24] . Finally, treatment of TNBC with 292 the anti-depressant fluoxetine (0.5 µM) caused AMPK activation and substantial 293 reductions in cellular viability [25] . Taken together, these studies and ours suggest the 294 merit in targeting the AMPK signaling pathway for the treatment of breast cancer. 295
We found that low micromolar concentrations of FND-4b substantially reduced 296 the growth of TNBC. This is particularly important because of the inherent 297 aggressiveness of TNBC that has higher rates of recurrence and metastasis than other 298 breast cancer subtypes [3] . The seriousness of TNBC is further amplified by the fact that 299 most breast cancer deaths result from metastatic lesions [2] . The difficulty in developing 300 treatments for TNBC is due to the lack of the estrogen receptor and HER2 amplification. 301
Drugs that target these proteins, such as trastuzumab and tamoxifen, are ineffective in 302 TNBC. Instead, patients with TNBC typically receive a drug cocktail that damages 303 normal cells in addition to the tumor and leads to significant side effects. Current efforts 304 are focused on developing drugs that specifically target proteins or pathways that are 305 exclusively altered in TNBC. Since expression of AMPK and pAMPK is lower in breast cancer than normal tissue, this signaling pathway attracted our attention as an option for 307 targeted therapy [30] [31] [32] . 308 AMPK activation resulted in substantial decreases in cell proliferation in all breast 309 cancer subtypes that were tested. These reductions in growth were due to AMPK's 310 ability to regulate the cell cycle both directly and indirectly. Directly, AMPK activation can 311 attenuate levels of cyclin D1, an important protein that controls cell cycle arrest during 312 the G1 phase [33] . Prior work in ovarian cancer has suggested that AMPK activation 313 causes degradation of cyclin D1 through a pathway involving glycogen synthase kinase 314 3β [33] . Once cyclin D1 is degraded, cells are prevented from progressing past the G1 315 phase [33] . We found that FND-4b-induced AMPK activation resulted in substantial 316 decreases in cyclin D1 expression, resulting in cell cycle arrest. Indirectly, AMPK 317 activation can affect the cell cycle through effects on mTOR and cellular metabolism. 318 AMPK downregulates flux through the mTOR pathway, which can control the cell cycle 319 through its downstream effectors S6 kinase 1 (S6K1) and eukaryotic translation initiation 320 factor 4E-binding protein 1 [34] . In our study, we measured mTOR activity by blotting for 321 levels of phosphorylated ribosomal protein S6, which is downstream from S6K1. We 322 found decreases in S6 phosphorylation with FND-4b-induced AMPK activation, 323 indicating less mTOR flux and cell cycle progression. Additionally, AMPK affects cell 324 metabolism by phosphorylating and inhibiting ACC, which is the rate-limiting step in fatty 325 acid synthesis. As a result, de novo lipogenesis is inhibited. Fatty acids are required for 326 progression through the cell cycle-notably, during the G 1 -S and G 2 -M phases-and in 327 their absence, cells will be unable to complete mitosis [16] . Instead they will be arrested 328 at the G2-M checkpoint [16] . We showed that FND-4b-induced AMPK activation led to 329 increased ACC phosphorylation, signifying less fatty acid synthesis and flux through the 330 cell cycle. 331
In addition to inducing cell cycle arrest, AMPK can also act as a tumor 332 suppressor by causing apoptosis [32] . We found that FND-4b causes apoptosis in a 333 dose-dependent manner in ER+BC cells with ELISA cell death assays. We also showed 334 clear increases in levels of cleaved PARP-an apoptotic indicator-in MCF-7 cells. 335 TNBC cells were more resistant to apoptosis from FND-4b, but there was apoptosis in 336 MDA-MB-231 cells with 10 µM treatment. Additionally, we found increases in cleaved 337 PARP in MDA-MB-231 and HCC-1806 cells with western blot. Taken together, these 338 data indicate that ER+BC cells are more susceptible to FND-4b-induced apoptosis than 339 TNBC. However, as suggested in previous work, the effects of FND-4b on cell cycle 340 progression are more pronounced and consistent than on apoptosis [27] . 341
Conclusions
342
We have shown that the novel compound FND-4b can activate AMPK in ER+BC, 343 TNBC, and breast cancer stem cells. In addition, treatment with this compound can 344 dose-dependently decrease proliferation and increase apoptosis in breast cancer cells. 
